Amy Karger, MD, PhD

Associate Professor, Department of Laboratory Medicine and Pathology

Amy Karger

Contact Info

karge026@umn.edu

Office Phone 612-624-2150

Fax 612-899-5614

Office Address:
D211 Mayo Memorial Building
420 Delaware Street SE
Minneapolis, MN 55455

Mailing Address:
MMC 609 Mayo
8609
420 Delaware SE
Minneapolis, MN 55455

Mayo Clinic College of Medicine, 1998-2006

University of Minnesota (Clinical Pathology), 2008-2011

University of Minnesota (Clinical Chemistry), 2011-2013

PhD, Mayo Clinic College of Medicine (Biomedical Sciences), 1998-2006

Massachusetts Institute of Technology (Chemical Engineering and Biology), 1994-1998

Summary

Dr. Karger is a member of the Division of Molecular Pathology and Genomics and a faculty investigator in the Advanced Research and Diagnostics Laboratory (ARDL). Her research focuses on predicting and delaying the progression of chronic kidney disease. Dr. Karger serves as a principal investigator with the Preventing Early Renal Loss in Diabetes (PERL) consortium. The consortium has undertaken a multi-center, double-blind, placebo-controlled, randomized clinical trial aimed at evaluating the efficacy of allopurinol in preventing kidney function loss in individuals with type 1 diabetes.

Dr. Karger is also a co-investigator with Dr. John Eckfeldt in the chronic kidney disease epidemiology collaboration (CKD-EPI). In this capacity she tests protein biomarkers such as cystatin C, beta-2 microglobulin and beta trace protein to improve GFR estimating equations. Improved GFR estimates give clinicians the ability to detect disease progression at earlier stages. By detecting disease progression at earlier stages clinicians can in turn intervene therapeutically. Delaying renal failure delays the need for dialysis with its many potential complications and high costs.

Research

Publications

Clinical

Board Certifications

American Board of Pathology, Clinical Pathology, 2011